Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588246 | 1.00 | CYP1A2 (0.50) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| Hydrochloric Acid SCHEMBL1699166 | 0.98 | CYP1A2 (0.49) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL9348013 | 0.80 | MAPT (0.47) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL5234386 | 0.77 | CYP1A2 (0.45) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL13629286 | 0.76 | CA12 (0.52) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL29572479 | 0.75 | CYP1A2 (0.50) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL2357532 | 0.75 | CYP1A2 (0.50) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL699878 | 0.73 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL2127320 | 0.73 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2GAATDP2NSD2 | |
| SCHEMBL1185191 | 0.73 | CYP1A2 (0.49) | CYP1A2SMN1; SMN2GAATDP2NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879892-A2 | 2-PYRROLIDONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND PAIN | XENON PHARMACEUTICALS INC. (CA) | 2008-01-23 | — | — | EP | claimed |
| WO-2006113875-A2 | 2 - PYRROLIDONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS AND PAIN | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | claimed |
| EP-1399155-A4 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMA (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1399155-A2 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2001006984-A2 | SMALL MOLECULES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASE | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-01 | — | — | WO | claimed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-8957219-B2 | Acetic acid amide derivative having inhibitory activity on endothelial lipase | SHIONOGI & CO., LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2014-09-25 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8470849-B2 | 7-azaindole derivatives as selective 11-β-hydroxysteroid dehydrogenase type 1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-2585462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2247589-B1 | 7-AZAINDOLE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | MERCK PATENT GMBH (DE) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | SHIONOGI & CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2247589-A1 | 7-AZAINDOLE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Merck Patent GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100267761-A1 | 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors | MERCK PATENT GESELLSCHAFT | 2010-10-21 | — | — | US | disclosed |
| WO-2009059666-A1 | 7-AZAINDOLE DERIVATIVES AS SELECTIVE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | MERCK PATENT GMBH (DE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008046082-A2 | USE OF HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251386-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | LIPG, CEL, LIPA | CYP1A2 1355/4885SMN1; SMN2 4521/4885GAA 765/4885 |
| US-20140288302-A1 | ACETIC ACID AMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY ON ENDOTHELIAL LIPASE | LIPG, CEL, FFAR3 | CYP1A2 967/4885SMN1; SMN2 4168/4885GAA 1078/4885 |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | CYP1A2 4660/4885SMN1; SMN2 2681/4885GAA 1047/4885 |
| US-20100267761-A1 | 7-Azaindole Derivatives as Selective 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors | HSD11B1, HSD17B1, HSD11B2 | CYP1A2 69/4885SMN1; SMN2 4116/4885GAA 728/4885 |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | CYP1A2 181/4885SMN1; SMN2 3762/4885GAA 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.